One in 5 adults has a lifetime diagnosis of bipolar disorder or major depressive disorder, ∼17% (12% for men and 25% for women) of whom are diagnosed with major depressive disorder and 2%--4% with bipolar disorder.[@R1]--[@R3] The yearly costs of depression and bipolar disorder in the United States are \$100 billion and \$151 billion, respectively.[@R4],[@R5] Mood disorders are associated with decreased earnings,[@R6] increased use of health care for other medical conditions, and premature death.[@R7],[@R8] Mood disorders can be chronic and difficult to treat; even after multiple, sequential interventions, only 50% of those with depression[@R9] and 30% with bipolar disorder[@R10] achieve remission.

Clinical research investigating interventions, such as those designed to treat mood disorders and other mental health conditions, has traditionally been conducted through carefully controlled trials.[@R11] However, typical research trials are limited in their ability to generalize findings to the larger population due to study restrictions, such as limited inclusion and extensive exclusion criteria and geographical limitations.[@R12] Such studies often do not allow for comparative arms that are representative of a real clinical care setting, or they examine outcomes that the patients in the population under study do not find helpful or want prioritized.[@R11],[@R13] Patient-centered methodological approaches, such as comparative effectiveness research, allow researchers to address this inability to generalize studies while also including patients with expertise through experience in the research process.[@R14]

MoodNetwork is an innovative approach to conducting clinical research for mood disorders that is designed to address typical research trial barriers. It is a collaboration of clinicians, researchers, patients, caregivers, and other advocates that form an online community designed to conduct comparative effectiveness research on mood disorders. MoodNetwork aims to address the difficulties in treating mental health conditions by giving individuals an opportunity to openly discuss their conditions, challenge the stereotypes associated with mental illness, and suggest clinical practices and research topics. By bringing together a large, diverse group of individuals with mood disorders interested in focusing on patient-reported outcomes and patient priorities in research, MoodNetwork has the potential to identify and investigate the factors that are of most importance to study participants. The primary aim of this report is to share lessons learned from developing MoodNetwork; a secondary aim is to examine trends in enrollment and discuss future directions for the Network.

METHODS
=======

Participants
------------

IRB approval was obtained before beginning the study. As of June 1, 2017, MoodNetwork has enrolled 4103 participants between the ages of 18 and 86. Online informed consent was obtained before collecting any study information. Participants were excluded if they were under the age of 18.

Procedure
---------

The founders of MoodNetwork collaborated with clinicians, researchers, patients, caregivers, and key patient advocacy groups to develop a website that promotes inclusion, equality, and a balanced perspective on mood disorders. Patient stakeholders from various backgrounds serve on MoodNetwork's team, including leaders from the International Bipolar Foundation (IBPF), Depression and Bipolar Support Alliance (DBSA), Anxiety and Depression Association of America (ADAA), National Organization for People of Color Against Suicide (NOPCAS), and National Alliance on Mental Illness (NAMI). These stakeholder and advocacy group members developed the website, web-based surveys, and recruitment materials with the goal of reducing stigma and maximizing the generalizability of content to participants with mood disorders.

Assessments
-----------

When participants enroll in MoodNetwork, they provide demographic information, such as race, ethnicity, age, marital status, and sex. Once enrolled, participants are able to complete several types of tools and surveys. These include a research priorities survey, which asks participants to select research topics that are of importance to them, as well as questionnaires designed to help track mood. In addition to questionnaire data, qualitative data are collected from MoodNetwork forums, which serve as a portal for open discussions for all MoodNetwork participants.

RESULTS
=======

Most (96.9%) MoodNetwork participants report experiencing depression at some point in their lives, and 79.7% endorse past episodes of mania or hypomania. The mean age of participants is 42 (SD=13.0; range, 18--86). The majority of the sample is female (78.2%), with 19.0% being male, 0.5% ambiguous sex, and 2.3% other or unknown (Table [1](#T1){ref-type="table"}). The MoodNetwork sample consists of mostly white participants (83.2%).

###### 

MoodNetwork Participant Demographics
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Figure [1](#F1){ref-type="fig"} shows enrollment over time for MoodNetwork. After an initial spike in recruitment in the first 60 days (10 participants/d) as individuals from our advocacy partners joined, enrollment has been steady (5 participants/d).

![MoodNetwork enrollment per month (2015--2017).](mlr-56-s48-g002){#F1}

The 3 most important research topics voted on by participants are reducing stigma (11.4% of votes), alleviating symptoms (11.0%), and reducing barriers to care (9.9%; Table [2](#T2){ref-type="table"}). Participants provide qualitative data with their forum responses, such as through comments on stigma and their loneliness in living with these conditions (Table [3](#T3){ref-type="table"}). Stakeholders involved in the study help generate strategies to address gaps brought up by qualitative feedback (forums) and quantitative responses (surveys), which include strategies that they perceive as key to reducing stigma and increasing enrollment within the MoodNetwork community. Using the "research priorities" survey, MoodNetwork participants and stakeholders have prioritized mental health stigma, an issue that continues to be a national and global problem and impacts the treatment and research of mood disorders.

###### 

Preferred Research Topics for MoodNetwork
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###### 

Selected Qualitative Feedback From MoodNetwork Participants
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The 5 main strategies that may help facilitate recruitment to MoodNetwork and other online programs that adopt this innovative approach to research are: (1) simplifying the language of the website and recruitment materials; (2) removing messaging that separates researchers and clinicians from patients and caregivers ("us" vs. "them"); (3) focusing on wellness and positive messaging; (4) improving access to materials developed by MoodNetwork and its collaborators by widely disseminating them through our advocacy partners; and (5) targeting recruitment toward specific subpopulations to increase their representation (Table [4](#T4){ref-type="table"}).

###### 

Strategies for Reducing Stigma and Encouraging People to Speak Out
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DISCUSSION
==========

MoodNetwork has recruited a relatively large sample (ie, over 4000) of individuals with mood disorders to provide longitudinal patient-reported outcomes. Consistent with other online registries, 78.2% of participants are female. In addition, 78.8% have self-reported bipolar disorder rather than major depressive disorder, and racial and ethnic diversity are limited. The underrepresentation of these populations is explained by previous research indicating that minority populations and men are less likely to seek care for mental health conditions.[@R15]--[@R17]

MoodNetwork's original recruitment goal was to enroll a community of 20,000 individuals with mood disorders. We are underenrolled, and progress toward this goal has been slower than anticipated. Our enrollment data, stakeholder input, and research priorities suggest that new strategies that target minority groups and individuals with depression could bolster recruitment for MoodNetwork, especially because a necessary component of this innovative research approach is generalizability to all people with mood disorders. In addition, participants indicate how they heard about the Network when they first register for the community. We use these data to focus our recruitment efforts on common referral sources.

As evidenced by participants' research priorities, decreasing stigma is an important future direction for MoodNetwork. Stigma surrounding mental health conditions has been linked to increased depression, poorer quality of life, low self-esteem, and fewer employment opportunities.[@R18]--[@R20] Moreover, in our effort to build MoodNetwork, we have consistently received feedback that people are nervous to join, as they do not want to be affiliated with a Network about mood disorders. Thus, MoodNetwork has realized that, to continue to embrace an innovative approach to patient-centered research, we must focus on reducing the stigma surrounding mood disorders.

On the basis of input from our stakeholders, MoodNetwork identified 5 strategies to reduce stigma within the MoodNetwork community (Table [4](#T4){ref-type="table"}). We believe that a focus on increasing the diversity of MoodNetwork will help reduce stigma by creating an open community that represents the universal nature of mood disorders. In representing a diverse community of individuals with mood disorders to both potential participants and current participants, MoodNetwork will communicate the important message that no person is alone in his or her diagnosis. MoodNetwork has worked closely with its stakeholder partners to use these strategies. For example, patients with depression or bipolar disorder often have difficulties with concentration, focus, and retention of details. To address this, we streamlined language throughout the MoodNetwork website to ensure that it is presented in small, easy-to-read chunks. We worked closely with our patient partners to determine the best way to present information to the specific population studied by MoodNetwork. We also keep all video material \<5 minutes long. To promote a collaborative research environment, we ask patient partners what they want MoodNetwork to focus on in future research projects (Table [3](#T3){ref-type="table"}). We also focus on and promote using positive language that describes living well with mood disorders as opposed to calling these conditions illnesses or saying that people with these conditions need to be cured. Finally, MoodNetwork plans on making aspects of the website that are currently for members only, such as surveys and feedback, available to the public or any visitor of MoodNetwork (before signing up or enrolling), as our stakeholders believe that this is key to building trust in the MoodNetwork team and project and encouraging more participants to enroll.

Perhaps most noteworthy, we have shifted our focus from large-scale, general messaging to "get everyone" with a mood disorder to targeting specific subpopulations, such as African American male fraternities, individuals with unipolar depression, and men through the Australian men's network. This strategy has helped improve recruitment of both men and members of minority groups, but given that we are targeting smaller groups of people, these campaigns tend to bring in fewer participants. However, recognizing and understanding that stigma and anxiety surrounding mood disorders could be contributing to slower enrollment, our team of stakeholders, patient partners, clinicians, and researchers feels that we need targeted, meaningful, patient-centered messaging to create trust and promote understanding of MoodNetwork's mission.

MoodNetwork is actively working with its stakeholders and participants to create a community of individuals with mood disorders to participate in comparative effectiveness research. We hope to give patients who may feel disenfranchised by their conditions a voice by encouraging them to discuss their experiences and share their priorities for future research. This is a necessary component to building the Network and represents a new way of conducting research on mood disorders. MoodNetwork is only as strong as its numbers. We have learned that stigma has greatly contributed to slower recruitment and thus, has stalled this innovation in research. By engaging a large and diverse group of participants at MoodNetwork, we hope to further understand the issue of stigma and how to reduce it through systematic investigation and comparative effectiveness research.
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